Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GLSI
Strong SellSinkerGreenwich LifeSciences, Inc. · Healthcare · United States · $230M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery. The company's competitive position is anchored by its ongoing Phase III clinical trial (FLAMINGO-01) targeting HER2/neu-positive breast cancer. As a niche oncology player, Greenwich operates with a highly focused pipeline aimed at addressing unmet needs in post-surgical cancer care.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.61 | -0.69 | -1.34 | -1.43 | — | -1.59 | -1.39 | -1.17 | — |
| Shares | 12.8M | 12.8M | 13.2M | 14.3M | +11.3% | 14.7M | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | 13.2M | 6.7M | 0.9M | 0.4M | -70.1% | — | — | — | — |
| Op CF | -6.2M | -6.5M | -7.3M | -9.9M | — | -12.5M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — |
| Fin CF | -7.5M | 0 | 4.4M | 12.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GLSI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GLSI | Greenwich LifeSciences, Inc.(you) | $230M | 4 | Strong Sell |
| NMRA | Neumora Therapeutics, Inc. | $261M | 5 | Strong Sell |
| ALEC | Alector, Inc. | $261M | 5 | Strong Sell |
| ARMP | Armata Pharmaceuticals, Inc. | $200M | 1 | Strong Sell |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $211M | 7 | Strong Sell |
| LCTX | Lineage Cell Therapeutics, Inc. | $281M | 5 | Strong Sell |
| TARA | Protara Therapeutics, Inc. | $226M | 9 | Strong Sell |
| HUMA | Humacyte, Inc. | $181M | 2 | Strong Sell |
| RNA | Atrium Therapeutics, Inc. | $233M | 11 | Strong Sell |
| NBP | NovaBridge Biosciences | $213M | 10 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%